Ignite Creation Date:
2024-05-06 @ 2:08 PM
Last Modification Date:
2024-10-26 @ 1:25 PM
Study NCT ID:
NCT04221919
Status:
NOT_YET_RECRUITING
Last Update Posted:
2020-01-09
First Post:
2020-01-05
Brief Title:
Different β -Blockers in STEMI and Primary PCI
Sponsor:
Qilu Hospital of Shandong University
Organization:
Qilu Hospital of Shandong University
Study Overview
Official Title:
Different β -Blockers in Patients With ST-segment Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Status:
NOT_YET_RECRUITING
Status Verified Date:
2020-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Carvedilol target dose 50 mg daily Bisoprolol target dose 10 mg daily Metoprolol tartrate target dose 150 mg daily Metroprolol succinate target dose 200 mg daily
Detailed Description:
The investigators will investigate the efficacy and safety of different β -blockers as well as heart rate variability in STEMI patients undergoing primary PCI
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None